MA52422A - Imidazopyrimidines et triazolopyrimidines en tant qu'inhibiteurs a2a/a2b - Google Patents

Imidazopyrimidines et triazolopyrimidines en tant qu'inhibiteurs a2a/a2b

Info

Publication number
MA52422A
MA52422A MA052422A MA52422A MA52422A MA 52422 A MA52422 A MA 52422A MA 052422 A MA052422 A MA 052422A MA 52422 A MA52422 A MA 52422A MA 52422 A MA52422 A MA 52422A
Authority
MA
Morocco
Prior art keywords
imidazopyrimidines
triazolopyrimidines
inhibitors
Prior art date
Application number
MA052422A
Other languages
English (en)
Inventor
Pei Gan
Heeoon Han
Chunhong He
Taisheng Huang
Matthew S Mccammant
Chao Qi
Ding-Quan Qian
xiaozhao Wang
Liangxing Wu
Wenqing Yao
Zhiyong Yu
Fenglei Zhang
Le Zhao
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of MA52422A publication Critical patent/MA52422A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA052422A 2018-02-27 2019-02-26 Imidazopyrimidines et triazolopyrimidines en tant qu'inhibiteurs a2a/a2b MA52422A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862635926P 2018-02-27 2018-02-27
US201862718216P 2018-08-13 2018-08-13
US201862721312P 2018-08-22 2018-08-22
US201962793015P 2019-01-16 2019-01-16

Publications (1)

Publication Number Publication Date
MA52422A true MA52422A (fr) 2021-01-06

Family

ID=65911247

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052422A MA52422A (fr) 2018-02-27 2019-02-26 Imidazopyrimidines et triazolopyrimidines en tant qu'inhibiteurs a2a/a2b

Country Status (19)

Country Link
US (4) US20190292188A1 (fr)
EP (1) EP3759112A1 (fr)
JP (2) JP7474709B2 (fr)
KR (1) KR20200139153A (fr)
CN (2) CN112384515B (fr)
AU (2) AU2019227607C1 (fr)
BR (2) BR112020017421A2 (fr)
CA (1) CA3092470A1 (fr)
CL (2) CL2020002198A1 (fr)
CO (1) CO2020011908A2 (fr)
CR (2) CR20200441A (fr)
EC (1) ECSP20060827A (fr)
IL (2) IL303087B2 (fr)
MA (1) MA52422A (fr)
MX (2) MX2020008949A (fr)
PE (2) PE20251291A1 (fr)
PH (1) PH12020551332A1 (fr)
TW (2) TWI853802B (fr)
WO (1) WO2019168847A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190129851A (ko) * 2017-03-16 2019-11-20 지앙수 헨그루이 메디슨 컴퍼니 리미티드 헤테로아릴[4,3-c]피리미딘-5-아민 유도체, 이의 제조 방법 및 이의 의학적 용도
EP3611174B1 (fr) * 2017-04-07 2022-06-08 Medshine Discovery Inc. Dérivé de [1,2,4] triazolo [1,5-c] pyrimidine en tant qu'inhibiteur du récepteur a2a
CA3070073A1 (fr) 2017-07-18 2019-01-24 Nuvation Bio Inc. Composes de 1,8-naphthyridinone et leurs utilisations
JP2020527588A (ja) 2017-07-18 2020-09-10 ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎ Ｂｉｏ Ｉｎｃ． アデノシンアンタゴニストとしてのヘテロ環式化合物
AU2019227607C1 (en) 2018-02-27 2023-07-20 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
EP3810610A1 (fr) 2018-05-18 2021-04-28 Incyte Corporation Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
CN117304191A (zh) 2018-07-05 2023-12-29 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
AR116315A1 (es) * 2018-09-12 2021-04-21 Dizal Jiangsu Pharmaceutical Co Ltd Compuestos de triazolo-pirimidina y usos de los mismos
JP2022507734A (ja) 2018-11-20 2022-01-18 メルク・シャープ・アンド・ドーム・コーポレーション 置換アミノトリアゾロピリミジン及びアミノトリアゾロピラジンアデノシン受容体アンタゴニスト、医薬組成物及びそれらの使用
US12414952B2 (en) 2018-11-20 2025-09-16 Merck Sharp & Dohme Llc Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
WO2020108590A1 (fr) * 2018-11-30 2020-06-04 上海拓界生物医药科技有限公司 Pyrimidine et dérivé hétérocycle pentagonal de nitrogène, leur procédé de préparation et applications médicales
JP7414827B2 (ja) 2018-12-20 2024-01-16 インサイト・コーポレイション アクチビン受容体様キナーゼ－２の阻害剤としてのイミダゾピリダジン及びイミダゾピリジン化合物
US11254670B2 (en) 2019-01-18 2022-02-22 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
WO2020150674A1 (fr) 2019-01-18 2020-07-23 Nuvation Bio Inc. Composés hétérocycliques en tant qu'antagonistes de l'adénosine
TWI829857B (zh) * 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
PH12022550470A1 (en) * 2019-08-26 2023-02-27 Incyte Corp Triazolopyrimidines as a2a / a2b inhibitors
KR20210061202A (ko) 2019-11-19 2021-05-27 일동제약(주) 벤조나이트릴이 치환된 축합 피리미딘 유도체 및 그의 의약 용도
EP4084870A1 (fr) 2020-01-03 2022-11-09 Incyte Corporation Polythérapie à base d'un inhibiteur de cd73 et d'inhibiteurs du récepteur de l'adénosine a2a/a2b
CR20220317A (es) 2020-01-03 2022-09-02 Incyte Corp Anticuerpos anti-cd73 y usos de estos
CN115279766B (zh) * 2020-01-03 2025-05-02 因赛特公司 包含a2a/a2b和pd-1/pd-l1抑制剂的组合疗法
WO2021156439A1 (fr) * 2020-02-06 2021-08-12 Astrazeneca Ab Composés de triazole utiles en tant qu'antagonistes du récepteur de l'adénosine
CN111362939B (zh) * 2020-04-26 2021-08-03 山东梅奥华卫科技有限公司 一种帕布昔利布母核结构化合物的制备方法
JP2024502005A (ja) * 2020-12-29 2024-01-17 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤、ｐｄ－１／ｐｄ－ｌ１阻害剤、及び抗ｃｄ７３抗体を含む併用療法
US12065444B2 (en) 2021-11-19 2024-08-20 Crossignal Therapeutics, Inc. Substituted tetrazolo[1,5-a]pyrazines and tetrazolo[1,5-c]pyrimidines as adenosine receptor antagonists
WO2023246846A1 (fr) * 2022-06-23 2023-12-28 成都恒昊创新科技有限公司 Inhibiteur de ferroptose non chélatant et non réducteur, son procédé de préparation et son utilisation
KR102621694B1 (ko) * 2022-09-15 2024-01-08 주식회사 스탠다임 아데노신 a2a 수용체 길항제 및 이의 용도
CN120022278A (zh) * 2023-11-22 2025-05-23 英诺湖医药(杭州)有限公司 用于治疗癌症的化合物

Family Cites Families (261)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP0590058B1 (fr) 1991-06-14 2003-11-26 Genentech, Inc. ANTICORP HUMANISE specifique pour heregulin
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
EP0859841B1 (fr) 1995-08-18 2002-06-19 MorphoSys AG Banques de proteines/(poly)peptides
DE19629378A1 (de) 1996-07-20 1998-01-29 Boehringer Ingelheim Kg Neue Triazolopurine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO1998042711A1 (fr) * 1997-03-24 1998-10-01 Kyowa Hakko Kogyo Co., Ltd. DERIVES [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINIQUES
ES2342240T3 (es) 1998-08-11 2010-07-02 Novartis Ag Derivados de isoquinolina con actividad que inhibe la angiogenia.
KR20010087361A (ko) 1998-09-22 2001-09-15 히라타 다다시 [1,2,4]트리아졸로[1,5-ｃ]피리미딘 유도체
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
IL146005A0 (en) 1999-05-07 2002-07-25 Genentech Inc Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
MXPA02001878A (es) 1999-08-23 2003-08-20 Dana Farber Cancer Inst Inc Moleculas b7-4 novedosas y usos de las mismas.
US6355653B1 (en) 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
CA3016482A1 (fr) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research Nouvelle molecule immunoregulatrice b7-h1,
US6803192B1 (en) 1999-11-30 2004-10-12 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
WO2001080884A1 (fr) 2000-04-25 2001-11-01 Idec Pharmaceuticals Corporation Administration intrathecale de rituximab pour le traitement des lymphomes du systeme nerveux central
PT1283839E (pt) 2000-05-26 2005-08-31 Schering Corp Antagonistas do receptor a2a da adenosina
EP1294358B1 (fr) 2000-06-28 2004-08-18 Smithkline Beecham Plc Procede de broyage par voie humide
HUP0700086A2 (en) 2000-08-11 2007-05-29 Eisai Co Ltd 2-aminopyridine compounds, use thereof as drugs and pharmaceutical compositions containing them
CN101555283B (zh) 2001-01-17 2012-03-21 生物权威国际有限公司 针对非功能性p2x7受体的抗体及其在癌症和其它病情的诊断和治疗中的用途
US7794710B2 (en) 2001-04-20 2010-09-14 Mayo Foundation For Medical Education And Research Methods of enhancing T cell responsiveness
WO2002096363A2 (fr) 2001-05-30 2002-12-05 Alteon, Inc. Methode de traitement de maladies fibreuses ou d'autres indications
US6806268B2 (en) 2001-05-30 2004-10-19 Alteon, Inc. Method for treating glaucoma V
CN100391958C (zh) 2001-09-19 2008-06-04 安万特医药股份有限公司 化合物
WO2003031587A2 (fr) 2001-10-09 2003-04-17 The Regents Of The University Of California Utilisation d'inhibiteurs de stat-6 comme agents therapeutiques
PT1441737E (pt) 2001-10-30 2006-12-29 Dana Farber Cancer Inst Inc Derivados de estrutura como inibidores da actividade do receptor de tirosina cinase flt3
EP1456652A4 (fr) 2001-11-13 2005-11-02 Dana Farber Cancer Inst Inc Agents modulant l'activite de cellules immunes et procedes d'utilisation associes
US6921762B2 (en) 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
TW200300686A (en) * 2001-11-30 2003-06-16 Schering Corp Adenosine A2a receptor antagonists
NZ534069A (en) 2002-01-22 2007-03-30 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
JPWO2003068776A1 (ja) 2002-02-15 2005-06-02 協和醗酵工業株式会社 ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AU2003272886A1 (en) 2002-09-24 2004-04-19 Kyowa Hakko Kogyo Co., Ltd. (1,2,4)-TRIAZOLO(1,5-c)PYRIMIDINE DERIVATIVE
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
AU2004205631A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
WO2004072266A2 (fr) 2003-02-13 2004-08-26 Kalobios Inc. Ingenierie de l'affinite des anticorps par un remplacement complementaire en serie guide par epitope
GB0303910D0 (en) 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
WO2004079013A1 (fr) 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) utilisee dans le diagnostic et le traitement du cancer du pancreas
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
JP4736043B2 (ja) 2003-03-14 2011-07-27 小野薬品工業株式会社 含窒素複素環誘導体およびそれらを有効成分とする薬剤
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
EP1633756B1 (fr) 2003-04-09 2008-12-24 Biogen Idec MA Inc. Antagonistes de recepteur d'adenosine a2a
EP1618109A2 (fr) * 2003-04-09 2006-01-25 Biogen Idec MA Inc. Triazolo [1,5-c]pyrimidines et pyrazolo [1,5-c]pyrimidines et procedes de preparation et d'utilisation de celles-ci
EP1615931A1 (fr) 2003-04-09 2006-01-18 Biogen Idec MA Inc. Triazolopyrazines et procedes de preparation et d'utilisation ce celles-ci
ME00426B (me) 2003-04-09 2011-10-10 Genentech Inc Liječenje autoimunih bolesti kod pacijenata sa neadekvatnim odgovorom na tnf-alfa inhibitor
EA200501924A1 (ru) 2003-06-10 2006-06-30 Киова Хакко Когио Ко., Лтд. Способ лечения тревожного расстройства
DK1639014T3 (da) 2003-06-13 2011-01-17 Biogen Idec Inc Aglycosyl-anti-CD154 (CD40-ligand)-antistoffer og anvendelser deraf
AU2004265101B2 (en) 2003-08-14 2009-06-11 F. Hoffmann-La Roche Ag Gabanergic modulators
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
WO2005020921A2 (fr) 2003-08-29 2005-03-10 Exelixis, Inc. Modulateurs c-kit et leurs procedes d'utilisation
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
GB0403819D0 (en) 2004-02-20 2004-03-24 Merck Sharp & Dohme New compounds
JP2007529496A (ja) 2004-03-19 2007-10-25 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 抗菌剤としてのイミダゾピリジン及びイミダゾピリミジン誘導体
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
US7687638B2 (en) 2004-06-04 2010-03-30 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US20060040944A1 (en) 2004-06-23 2006-02-23 Gilles Gosselin 5-Aza-7-deazapurine derivatives for treating Flaviviridae
JP2008504294A (ja) 2004-06-25 2008-02-14 アムジエン・インコーポレーテツド サイトカイン介在疾患および他の疾患の治療において有用な縮合トリアゾールおよびインダゾール
SG156643A1 (en) 2004-10-15 2009-11-26 Verisign Inc One time password
EP1812439B2 (fr) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Inhibiteurs de kinase
US20060211739A1 (en) 2005-02-08 2006-09-21 Arturo Perez-Medrano Use of selective P2X7 receptor antagonists
EP3530736A3 (fr) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Anticorps monoclonaux humains pour mort programmée 1 (pd-1) et procédés de traitement du cancer à l'aide d'anticorps anti-pd-1 seuls ou combinés à d'autres formulations immunothérapeutiques
EP1883424A2 (fr) 2005-05-18 2008-02-06 Biogen Idec Inc. Methodes pour traiter des troubles fibrotiques
WO2006129626A1 (fr) 2005-05-30 2006-12-07 Kyowa Hakko Kogyo Co., Ltd. Procede de fabrication d'un derive de [1,2,4]triazolo[1,5-c]pyrimidine
JPWO2006132275A1 (ja) 2005-06-07 2009-01-08 協和醗酵工業株式会社 運動障害の予防および／または治療剤
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
JP4986451B2 (ja) 2005-06-30 2012-07-25 信一郎 礒部 マーキング剤
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
WO2007011759A2 (fr) 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibiteurs de la kinesine mitotique
EP1928237A4 (fr) 2005-09-02 2011-03-09 Abbott Lab Nouveaux heterocycles a base imidazo
EP1945644A2 (fr) 2005-11-10 2008-07-23 Schering Corporation Imidazopyrazines inhibant la proteine kinase
CA2630271C (fr) 2005-11-17 2014-04-08 Osi Pharmaceuticals, Inc. Inhibiteurs mtor bicycliques condenses
WO2007110868A2 (fr) 2006-03-28 2007-10-04 Atir Holding S.A. Composés hétérocycliques et leurs utilisations dans le traitement de troubles sexuels
EP2049518B1 (fr) 2006-05-31 2011-08-31 Takeda San Diego, Inc. Derives de l'indazole et de l'isoindazole comme agents de l'activation de glucokinase
HRP20100378T1 (hr) 2006-05-31 2010-08-31 Galapagos N.V. Spojevi triazolopirazina učinkoviti za tretman degenerativnih i upalnih bolesti
US7511050B2 (en) 2006-06-23 2009-03-31 Incyte Corporation Purinone derivatives as HM74A agonists
CA2656067C (fr) 2006-06-23 2014-08-12 Radius Health, Inc. Traitement de symptomes vasomoteurs par des modulateurs des recepteurs d'oestrogene selectifs
EP2975057A1 (fr) 2006-07-10 2016-01-20 Fujita Health University Nouvel anticorps anti-cd73
BRPI0713187A2 (pt) 2006-07-20 2012-10-16 Mehmet Kahraman método de inibir rho-quinase, método de tratamento de doença mediada por rho-quinase, composto e composição farmacêutica
DE102006041292A1 (de) 2006-09-01 2008-03-06 Henkel Kgaa Wasserstoffperoxid-Aktivierung mit N-Heterocyclen
WO2008037607A1 (fr) 2006-09-25 2008-04-03 Basf Se Composés hétérocycliques à teneur en groupe carbonyle et leur utilisation pour lutter contre des champignons phytopathogènes
WO2008056176A1 (fr) 2006-11-10 2008-05-15 Scottish Biomedical Limited Pyrazolopyrimidines utiles comme inhibiteurs de la phosphodiestérase
WO2008070599A1 (fr) 2006-12-05 2008-06-12 Chung-Ming Sun Composés d'indazole
DE102007012645A1 (de) 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
CN103204852A (zh) 2007-04-10 2013-07-17 H.隆德贝克有限公司 作为p2x7拮抗剂的杂芳基酰胺类似物
US8039505B2 (en) 2007-04-11 2011-10-18 University Of Utah Research Foundation Compounds for modulating T-cells
WO2008138843A1 (fr) 2007-05-10 2008-11-20 Galapagos N.V. Imidazopyridines et triazolopyrimidines utiles pour le traitement de maladies dégénératives et inflammatoires des articulations
WO2008141239A1 (fr) 2007-05-10 2008-11-20 Acadia Pharmaceuticals Inc. Imidazole [1,2-a] pyridines et composés présentant une activité au niveau des récepteurs cb2 cannabinoïdes
HUP0700395A2 (en) 2007-06-07 2009-03-02 Sanofi Aventis Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
CN101801966A (zh) 2007-07-18 2010-08-11 诺瓦提斯公司 双环杂芳基化合物和它们作为激酶抑制剂的用途
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
CN101842098A (zh) 2007-08-10 2010-09-22 基因实验室技术有限公司 用于治疗病毒感染的含氮的二环化学实体
US8062852B2 (en) 2007-10-01 2011-11-22 The Children's Hospital And Regional Medical Center Detection and treatment of autoimmune disorders
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
US20100261679A1 (en) 2007-10-18 2010-10-14 James Sutton CSF-1R, Inhibitors, Compositions, and Methods of Use
US20090118301A1 (en) 2007-11-02 2009-05-07 Arbor Vita Corporation Compositions and Methods for Treating Cancer
CA2704645A1 (fr) 2007-11-09 2009-05-14 The Salk Institute For Biological Studies Inhibiteurs non nucleosidiques de la transcriptase inverse
PE20091074A1 (es) 2007-12-13 2009-07-26 Bayer Healthcare Ag Triazolotriazinas y triazolopirazinas y su uso
AU2008343932B2 (en) 2007-12-19 2013-08-15 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
US7820665B2 (en) 2007-12-19 2010-10-26 Amgen Inc. Imidazopyridazine inhibitors of PI3 kinase for cancer treatment
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2009114870A2 (fr) 2008-03-14 2009-09-17 Intellikine, Inc. Inhibiteurs de kinases, et procédés d’utilisation associés
WO2009117421A2 (fr) 2008-03-17 2009-09-24 Kalypsys, Inc. Modulateurs hétérocycliques de gpr119 pour le traitement d’une maladie
CN102037157B (zh) 2008-03-21 2014-05-28 恩索恩公司 用多官能化合物促进金属对层压板的粘合力
US20090281089A1 (en) 2008-04-11 2009-11-12 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
US20110105457A1 (en) 2008-04-18 2011-05-05 Shionogi & Co., Ltd. Heterocyclic compound having inhibitory activity on pi3k
TWI473614B (zh) 2008-05-29 2015-02-21 Kyowa Hakko Kirin Co Ltd Anti-analgesic inhibitors
NZ590793A (en) 2008-07-23 2012-07-27 Kyowa Hakko Kirin Co Ltd Therapeutic agent for migraine
WO2010032874A1 (fr) 2008-09-19 2010-03-25 住友化学株式会社 Composition utilisée en milieu agricole
WO2010033906A2 (fr) 2008-09-19 2010-03-25 President And Fellows Of Harvard College Induction efficace de cellules souches pluripotentes au moyen de composés à petite molécule
WO2010036959A2 (fr) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Anticorps anti-pd-1, pd-l1, et pd-l2 humains et leurs utilisations
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
CN102264737A (zh) 2008-12-23 2011-11-30 雅培制药有限公司 抗病毒化合物
RU2505539C2 (ru) 2008-12-23 2014-01-27 Эбботт Лэборетриз Антивирусные соединения
EP2210891A1 (fr) 2009-01-26 2010-07-28 Domain Therapeutics Nouveaux ligands du récepteur de l'adénosine et leurs utilisations
WO2010089411A2 (fr) 2009-02-09 2010-08-12 Universite De La Mediterranee Anticorps pd-1 et anticorps pd-l1 et leurs utilisations
WO2010104306A2 (fr) 2009-03-07 2010-09-16 주식회사 메디젠텍 Compositions pharmaceutiques pour traiter ou prévenir des maladies causées par la translocation de gsk3 du noyau cellulaire au cytoplasme, contenant des composés inhibant la translocation de gsk3 du noyau cellulaire au cytoplasme
WO2011019780A1 (fr) 2009-08-11 2011-02-17 Bristol-Myers Squibb Company Azaindazoles comme modulateurs de la kinase btk et leur utilisation
UA111579C2 (uk) 2009-08-17 2016-05-25 Інтеллікіне Ллк ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ
WO2011060207A1 (fr) 2009-11-16 2011-05-19 Schering Corporation Composés tricycliques condensés possédant une activité antagoniste des récepteurs a2a de l'adénosine
EP2504028A4 (fr) 2009-11-24 2014-04-09 Amplimmune Inc Inhibition simultanée de pd-l1/pd-l2
WO2011078143A1 (fr) 2009-12-22 2011-06-30 塩野義製薬株式会社 Dérivés de pyrimidine et composition pharmaceutique les contenant
US20130022629A1 (en) 2010-01-04 2013-01-24 Sharpe Arlene H Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
EP2347769A1 (fr) 2010-01-20 2011-07-27 Glycotope GmbH Marqueurs de cellules souches de cancer et utilisations associées
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
RU2576662C2 (ru) 2010-03-18 2016-03-10 Энститю Пастер Корея Противоинфекционные соединения
UY33304A (es) 2010-04-02 2011-10-31 Amgen Inc Compuestos heterocíclicos y sus usos
GB201007187D0 (en) 2010-04-29 2010-06-09 Iti Scotland Ltd Ubiquitination modulators
WO2011153588A1 (fr) 2010-06-10 2011-12-15 Biota Scientific Management Pty Ltd Inhibiteurs de polymérase virale
US20120083498A1 (en) 2010-06-17 2012-04-05 Fatah Kashanchi Modulators of Viral Transcription, and Methods and Compositions Therewith
US9163087B2 (en) 2010-06-18 2015-10-20 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
CA2809331C (fr) 2010-08-27 2018-09-25 Merck Patent Gmbh Derives triazolopyrazine
KR102186969B1 (ko) 2010-10-25 2020-12-04 쥐원 쎄라퓨틱스, 인크. Cdk 억제제
EP2651405A2 (fr) 2010-12-14 2013-10-23 Electrophoretics Limited Inhibiteurs de caséine kinase 1 (ck1 )
JP6106603B2 (ja) 2011-01-11 2017-04-05 スノビオン プハルマセウトイカルス インコーポレイテッド ヘテロアリール化合物及びその使用方法
WO2012116237A2 (fr) 2011-02-23 2012-08-30 Intellikine, Llc Composés hétérocycliques et leurs utilisations
KR101606250B1 (ko) 2011-03-23 2016-03-24 암젠 인크 Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제
WO2012143796A2 (fr) 2011-04-21 2012-10-26 Institut Pasteur Korea Composés anti-inflammatoires
WO2012147890A1 (fr) 2011-04-27 2012-11-01 持田製薬株式会社 Nouveau dérivé d'azole
DE102011111400A1 (de) 2011-08-23 2013-02-28 Merck Patent Gmbh Bicyclische heteroaromatische Verbindungen
EP2604265A1 (fr) 2011-12-17 2013-06-19 Royal College of Surgeons in Ireland (RCSI) Antagonistes P2x7 en tant que traitement auxiliaire ou principal contre l'état de mal épileptique
WO2013106254A1 (fr) 2012-01-11 2013-07-18 Dow Agrosciences Llc Compositions pesticides et procédés qui leur sont associés
WO2013178572A1 (fr) 2012-05-30 2013-12-05 F. Hoffmann-La Roche Ag Composés triazolo en tant qu'inhibiteurs de pde10
EP2865671B1 (fr) 2012-06-22 2017-11-01 Sumitomo Chemical Company, Ltd Composé hétérocyclique fusionné
US20150197503A1 (en) 2012-07-27 2015-07-16 Bial-Portela & Cª, S.A. Process for the synthesis of substituted urea compounds
US9757379B2 (en) 2012-11-14 2017-09-12 The Board Of Regents Of The University Of Texas System Inhibition of HIF-2α heterodimerization with HIF1β (ARNT)
WO2014126580A1 (fr) 2013-02-15 2014-08-21 Dow Agrosciences Llc Compositions pesticides et processus associés à celles-ci
US10273243B2 (en) 2013-03-14 2019-04-30 The Trustees Of Columbia University In The City Of New York 4-phenylpiperidines, their preparation and use
US9090697B2 (en) 2013-03-15 2015-07-28 Bayer Healthcare Llc Methods for treating bleeding disorders
WO2014153424A1 (fr) 2013-03-19 2014-09-25 La Jolla Institute For Allergy And Immunology Réduction de diabète chez des patients recevant des inhibiteurs de l'hmg-coa réductase (statines)
BR112016001457A2 (pt) 2013-07-25 2017-08-29 Dana Farber Cancer Inst Inc Inibidores de fatores de transcrição e usos dos mesmos
WO2015157955A1 (fr) 2014-04-17 2015-10-22 Abbvie Inc. Inhibiteurs de tyrosine kinase de bruton (btk) hétérocyclique
WO2016007722A1 (fr) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines et triazolopyrazines utilisables comme inhibiteurs de lsd1
CN106604933B (zh) 2014-07-11 2021-08-10 文塔纳医疗系统公司 抗pd-l1抗体及其诊断用途
US9573948B2 (en) 2014-10-06 2017-02-21 Flatley Discovery Lab Triazolopyridine compounds and methods for the treatment of cystic fibrosis
US20180030144A1 (en) 2014-10-10 2018-02-01 Innate Pharma Cd73 blockade
WO2016055609A1 (fr) 2014-10-10 2016-04-14 Innate Pharma Blocage de cd73
RS62003B2 (sr) 2014-11-10 2025-01-31 Medimmune Ltd Vezujući molekuli specifični za cd73 i njihove upotrebe
EP3789403A1 (fr) 2014-11-11 2021-03-10 MedImmune Limited Combinaisons thérapeutiques contenant des anticorps anti-cd73 et des inhibiteurs du récepteur a2a et utilisations desdites combinaisons
JP6805142B2 (ja) 2014-11-21 2020-12-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｄ７３に対する抗体およびその使用
US10464950B2 (en) 2015-02-12 2019-11-05 Nissan Chemical Corporation Condensed heterocyclic compounds and pesticides
MX376835B (es) 2015-03-06 2025-03-07 Pharmakea Inc Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos.
EA201792205A1 (ru) 2015-04-03 2018-02-28 Инсайт Корпорейшн Гетероциклические соединения как ингибиторы lsd1
PE20231958A1 (es) 2015-07-30 2023-12-06 Macrogenics Inc Moleculas de union a pd-1 y metodos de uso de las mismas
WO2017064043A1 (fr) 2015-10-12 2017-04-20 Innate Pharma Agents de blocage de cd73
US20170107216A1 (en) 2015-10-19 2017-04-20 Incyte Corporation Heterocyclic compounds as immunomodulators
MD3377488T2 (ro) 2015-11-19 2023-02-28 Incyte Corp Compuși heterociclici ca imunomodulatori
CA3007646A1 (fr) 2015-12-09 2017-06-15 Bioatla, Llc Anticorps anti-cd73 humanises
ES2916874T3 (es) 2015-12-17 2022-07-06 Incyte Corp Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1
CA3009474A1 (fr) 2015-12-22 2017-06-29 Incyte Corporation Composes heterocycliques utilises comme immunomodulateurs
AU2016379425B2 (en) 2015-12-24 2021-11-11 Corvus Pharmaceuticals, Inc. Methods of treating cancer
MX383747B (es) 2016-02-24 2025-03-14 Pfizer Derivados de pirazolo[1,5-a]pirazin-4-ilo como inhibidores de quinasas janus (jak)
WO2017161028A1 (fr) 2016-03-16 2017-09-21 Kura Oncology, Inc. Inhibiteurs substitués de ménine-mll et méthodes d'utilisation
ES2906460T3 (es) 2016-05-06 2022-04-18 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
EP3464279B1 (fr) 2016-05-26 2021-11-24 Incyte Corporation Composés hétérocycliques comme immunomodulateurs
SG11201811414TA (en) 2016-06-20 2019-01-30 Incyte Corp Heterocyclic compounds as immunomodulators
TW201803871A (zh) * 2016-06-24 2018-02-01 英塞特公司 作為ＰＩ３Ｋ-γ抑制劑之雜環化合物
WO2018004478A1 (fr) 2016-06-29 2018-01-04 Hayat Kimya San. A. Ş. Procédé amélioré de production de tissu non tissé mou
EP3481869A4 (fr) 2016-07-11 2020-02-26 Corvus Pharmaceuticals, Inc. Anticorps anti-cd73
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
IL264955B (en) 2016-09-02 2022-06-01 Ironwood Pharmaceuticals Inc Fused bicyclic sgc stimulators
CA3046432A1 (fr) 2016-12-13 2018-06-21 Astellas Pharma Inc. Anticorps anti-cd73 humain
WO2018119263A1 (fr) 2016-12-22 2018-06-28 Incyte Corporation Composés hétérocycliques utilisés en tant qu'inducteurs de l'internalisation de pd-l1
EP4223369A1 (fr) 2016-12-22 2023-08-09 Incyte Corporation Composés immunomodulateurs et procédés d'utilisation
WO2018119236A1 (fr) 2016-12-22 2018-06-28 Incyte Corporation Dérivés de triazolo[1,5-a]pyridine en tant qu'immunomodulateurs
WO2018119221A1 (fr) 2016-12-22 2018-06-28 Incyte Corporation Dérivés pyridine utilisés en tant qu'immunomodulateurs
US10308644B2 (en) 2016-12-22 2019-06-04 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018119286A1 (fr) 2016-12-22 2018-06-28 Incyte Corporation Composés hétéroaromatiques bicycliques utilisés en tant qu'immunomodulateurs
CN110446709B (zh) 2017-01-23 2023-09-12 锐新医药公司 作为变构shp2抑制剂的二环化合物
CA3045376C (fr) 2017-01-24 2022-08-30 I-Mab Anticorps anti-cd73 et leurs utilisations
KR20190129851A (ko) 2017-03-16 2019-11-20 지앙수 헨그루이 메디슨 컴퍼니 리미티드 헤테로아릴[4,3-c]피리미딘-5-아민 유도체, 이의 제조 방법 및 이의 의학적 용도
WO2018187512A1 (fr) 2017-04-04 2018-10-11 Corvus Pharmaceuticals, Inc. Méthodes de traitement des tumeurs à taux de cd73 élevés
EP3611174B1 (fr) * 2017-04-07 2022-06-08 Medshine Discovery Inc. Dérivé de [1,2,4] triazolo [1,5-c] pyrimidine en tant qu'inhibiteur du récepteur a2a
WO2018215535A1 (fr) 2017-05-23 2018-11-29 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Nouvel anticorps anti-cd73 et utilisations associées
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
MX2019015885A (es) 2017-06-22 2020-09-10 Novartis Ag Moleculas de anticuerpo que se unen a cd73 y usos de las mismas.
AU2018294557A1 (en) 2017-06-30 2020-01-02 Ryvu Therapeutics S.A. Imidazo(1,2-a)pyrazine modulators of the adenosine A2A receptor
CN109535161B (zh) * 2017-09-22 2021-09-03 江苏恒瑞医药股份有限公司 三唑并嘧啶类衍生物、其制备方法及其在医药上的应用
MA50440A (fr) 2017-10-24 2020-09-02 Bayer Ag Imidazopyridinamides substituées et leur utilisation
MX2020004756A (es) 2017-11-16 2020-08-20 Novartis Ag Terapias de combinacion.
JP2021512109A (ja) 2018-01-31 2021-05-13 アプティニックス インコーポレイテッド スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用
PE20210455A1 (es) 2018-01-31 2021-03-08 Aptinyx Inc Moduladores del receptor nmda espiro-lactama y usos de los mismos
SG11202007739XA (en) 2018-02-17 2020-09-29 Astrazeneca Ab Arginase inhibitors and methods of use thereof
AU2019227607C1 (en) 2018-02-27 2023-07-20 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
WO2019170131A1 (fr) 2018-03-07 2019-09-12 复旦大学 Anticorps cd73 ciblé et conjugué anticorps-médicament, procédé de préparation associé et utilisations correspondantes
AU2019231172B2 (en) 2018-03-09 2023-08-24 Phanes Therapeutics, Inc. Anti-CD73 antibodies and uses thereof
CN119431579A (zh) 2018-03-09 2025-02-14 艾吉纳斯公司 抗cd73抗体及其使用方法
SMT202300065T1 (it) 2018-03-30 2023-05-12 Incyte Corp Composti eterociclici come immunomodulatori
US11220510B2 (en) 2018-04-09 2022-01-11 Incyte Corporation Pyrrole tricyclic compounds as A2A / A2B inhibitors
CA3096674A1 (fr) 2018-04-12 2019-10-17 Bristol-Myers Squibb Company Therapie combinee anticacner avec un antagoniste de cd73 et un antagoniste de l'axe pd-1/pd-l1
CN112752756B (zh) 2018-05-11 2024-06-25 因赛特公司 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物
EP3810610A1 (fr) 2018-05-18 2021-04-28 Incyte Corporation Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
KR20210030366A (ko) 2018-06-20 2021-03-17 인사이트 코포레이션 항-pd-1 항체 및 이의 용도
CN117304191A (zh) 2018-07-05 2023-12-29 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
MY210507A (en) 2018-08-13 2025-09-28 Hoffmann La Roche New heterocyclic compounds as monoacylglycerol lipase inhibitors
EP3837264A1 (fr) 2018-08-13 2021-06-23 F. Hoffmann-La Roche AG Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de monoacylglycérol lipase
MA53427B1 (fr) 2018-08-22 2024-06-28 Astrazeneca Ab Inhibiteurs de l'arginase et leurs méthodes d'utilisation
GB201813678D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics
AR116315A1 (es) 2018-09-12 2021-04-21 Dizal Jiangsu Pharmaceutical Co Ltd Compuestos de triazolo-pirimidina y usos de los mismos
JP2022503792A (ja) 2018-09-26 2022-01-12 クラ オンコロジー，インク． メニン阻害剤を用いた血液悪性腫瘍の処置
WO2020073945A1 (fr) 2018-10-10 2020-04-16 江苏豪森药业集团有限公司 Inhibiteur de dérivé bicyclique, son procédé de préparation et son utilisation
AR117188A1 (es) 2018-11-02 2021-07-21 Aicuris Gmbh & Co Kg Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (vhb)
US12414952B2 (en) 2018-11-20 2025-09-16 Merck Sharp & Dohme Llc Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
CN115925705B (zh) 2018-11-30 2024-12-31 江苏豪森药业集团有限公司 杂芳类衍生物调节剂、其制备方法和应用
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
TW202115059A (zh) 2019-08-09 2021-04-16 美商英塞特公司 Ｐｄ—１／ｐｄ—ｌ１抑制劑之鹽
PH12022550470A1 (en) 2019-08-26 2023-02-27 Incyte Corp Triazolopyrimidines as a2a / a2b inhibitors
JP7559059B2 (ja) 2019-09-30 2024-10-01 インサイト・コーポレイション 免疫調節剤としてのピリド［３，２－ｄ］ピリミジン化合物
EP4058461A1 (fr) 2019-11-11 2022-09-21 Incyte Corporation Formes salines et cristallines d'un inhibiteur de pd-1/pd-l1
CR20220317A (es) 2020-01-03 2022-09-02 Incyte Corp Anticuerpos anti-cd73 y usos de estos
CN115279766B (zh) 2020-01-03 2025-05-02 因赛特公司 包含a2a/a2b和pd-1/pd-l1抑制剂的组合疗法
IL302590A (en) 2020-11-06 2023-07-01 Incyte Corp Process for preparing PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
JP2024502005A (ja) 2020-12-29 2024-01-17 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤、ｐｄ－１／ｐｄ－ｌ１阻害剤、及び抗ｃｄ７３抗体を含む併用療法

Also Published As

Publication number Publication date
IL303087B2 (en) 2024-12-01
ECSP20060827A (es) 2020-12-31
CR20230030A (es) 2023-03-10
PE20211001A1 (es) 2021-06-01
TWI853802B (zh) 2024-09-01
JP2021515036A (ja) 2021-06-17
CA3092470A1 (fr) 2019-09-06
IL303087B1 (en) 2024-08-01
AU2019227607A1 (en) 2020-10-15
BR112020017421A2 (pt) 2020-12-22
AU2019227607B2 (en) 2023-04-27
KR20200139153A (ko) 2020-12-11
CN112384515A (zh) 2021-02-19
US20250313567A1 (en) 2025-10-09
PH12020551332A1 (en) 2021-09-06
WO2019168847A1 (fr) 2019-09-06
BR122023024273A2 (pt) 2024-02-20
IL276873A (en) 2020-10-29
US20230357255A1 (en) 2023-11-09
IL303087A (en) 2023-07-01
CO2020011908A2 (es) 2020-10-30
US20210139485A1 (en) 2021-05-13
CL2022003185A1 (es) 2023-05-19
JP7474709B2 (ja) 2024-04-25
JP7624476B2 (ja) 2025-01-30
JP2023123569A (ja) 2023-09-05
IL276873B2 (en) 2025-11-01
CN117903140A (zh) 2024-04-19
EP3759112A1 (fr) 2021-01-06
MX2020008949A (es) 2021-01-08
PE20251291A1 (es) 2025-05-14
MX2022014648A (es) 2022-12-15
US20190292188A1 (en) 2019-09-26
CL2020002198A1 (es) 2021-01-29
AU2019227607C1 (en) 2023-07-20
CN112384515B (zh) 2024-12-10
TW202000666A (zh) 2020-01-01
AU2022283611A1 (en) 2023-02-02
TW202400599A (zh) 2024-01-01
US11673894B2 (en) 2023-06-13
IL276873B1 (en) 2025-07-01
AU2022283611B2 (en) 2025-02-06
CR20200441A (es) 2021-03-15
TWI877770B (zh) 2025-03-21

Similar Documents

Publication Publication Date Title
IL284050A (en) Substituted pyrazolopyrimes and substituted purines and their use as ubiquitin specific-processing protease 1 (usp1) inhibitors
IL276873A (en) Midazopyrimidines and triazolopyrimidines as A2A /A2B inhibitors
IL279829A (en) Fused pyrazine derivatives as a2a / a2b inhibitors
MA49903A (fr) Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3
IL282372A (en) Haploid induction compositions and methods for use therefor
IL257486A (en) Methods and compositions for treating a proprotein convertase subtilisin kexin (pcsk9) gene-associated disorder
EP3280715A4 (fr) Nouvelles imidazo[1,5-a]pyridines substituées en 5ème ou 8ème position en tant qu'indoleamine et/ou tryptophane 2,3-dioxygénases
EP3518934A4 (fr) Inhibiteurs de l'adénosine 5'-nucléotidase
SMT202100122T1 (it) Coniugati anticorpo-farmaco anti-cmet e metodi per il loro uso
EP3544617A4 (fr) Agents arn modifiés à effet hors cible réduit
LT3429591T (lt) Pakeistojo tieno[2,3-d]pirimidino dariniai kaip menino-mll inhibitoriai ir jų panaudojimo būdai
MA52593A (fr) 1h-pyrazolo[4,3-b]pyridines en tant qu'inhibiteurs pde1
PL3889145T3 (pl) 8-cyjano-5-piperydyno-chinoliny jako antagoniści TLR7/8 oraz ich zastosowanie w leczeniu zaburzeń immunologicznych
IL246564A (en) 3-aryl-1-heterocyclic-pyrazolo [4,3- d] pyrimidine derivatives and their use in the treatment of diseases
DK3157571T3 (da) Fedtsyrer og deres anvendelse i konjugation med biomolekyler
IL258828A (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
IL261655B (en) Liposomal compositions and their uses in agriculture
MA54870A (fr) Pyrazolopyridines et triazolopyridines utilisées en tant qu'inhibiteurs a2a/a2b
HUE059050T2 (hu) Aminosavakat tartalmazó készítmények mitokondriális rendellenességgel összefüggõ betegségek kezelésében történõ alkalmazásra
EP3515914A4 (fr) Nouvelles imidazo[1,5-a]pyridines substituées en position 5 ou 8 en tant qu'indoleamine et/ou tryptophane 2,3-dioxygénases
DK3710036T3 (da) Stable ascorbic acid compositions and methods of using the same
IL269710A (en) 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers
LT3442975T (lt) 1,5-dihidro-4h-pirazol[3,4-d]pirimidin-4-onai ir 1,5-dihidro-4h-pirazol[4,3-c]piridin-4-onai kaip pde1 inhibitoriai
HRP20251395T1 (hr) Topikalne formulacije za isporuku spojeva inhibitora hedgehog signalnog puta i njihova uporaba
LT3347356T (lt) Tricikliniai sulieti piridin-2-ono dariniai ir jų naudojimas kaip brd4 inhibitorių